Hypertension and Dislipidemia Control in 115 Type 2 Diabetics: a Real-World 3 Year Experience

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: MON 776-795-Cardiometabolic Risk & Vascular Biology
Clinical
Monday, June 17, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board MON-794
Tiago Lopes Nunes da Silva*, Bernardo Dias Pereira, Henrique Vara Luiz, Andreia Veloza, Ana Catarina Matos, Isabel Manita, Maria Carlos Cordeiro, Luísa Raimundo and Jorge Portugal
Garcia de Orta Hospital, Almada, Portugal
In the patient with type 2 diabetes (DM2), hypertension (HTA) and dislipidemia control are very important treatment targets to prevent vascular complications.

The authors studied the prevalence and treatment of HTA and dislipidemia in 115 DM2 patients, during their first 3 years of follow-up in an Endocrinology Center. One-way ANOVA or paired t-test were used to study normally distributed variables.

At baseline, DM2 duration was 7 years, glomerular filtration rate (GFR) was 93 ml/min and 87 patients had HTA with average systolic and diastolic values of 136/76 mmHg. Anti-hypertensive drugs were administered to 95% of patients with HTA ((ACE inhibitors 18%, ACE inhibitors plus Thiazide 8%, Angiotensin Receptor Antagonists (ARA) plus Thiazide 7%)).

Dislipidemia was present in 90 patients, with mean total cholesterol (Tc) of 190 mg/dL, LDL cholesterol (cLDL) of 112 mg/dL, HDL cholesterol (cHDL) of 50 mg/dL, triglicerides of 154 mg/dL and non-HDL Cholesterol of 139 mg/dL. Only 41% were under pharmacological treatment (47% with sinvastatin; 17% with atorvastatin 13% with rosuvastatin and 6% with sinvastatin plus ezetimibe).

At the end of 3 years, GFR was 97 ml/min (NS), 95 patients had HTA (p<0,01), with average systolic and diastolic values of 137/71 mmHg (NS). The number of patients treated with anti-hypertensive drugs increased to 96% (ACE inhibitors 19%, ACE inhibitors plus Thiazide 9%, ARA plus Thiazide 7%).

Also, there was an increase of dislipidemic patients to 94 (NS), with a decrease in TC to 174 mg/dL (p<0, 05) and non-HDL to 124 mg/dL (p<0,001). The number of treated dislipidemic patients increased to 70% (44% with sinvastatin; 20% with rosuvastatin, 9% with atorvastatin, and 7,5% with sinvastatin plus ezetimibe) (p<0,01).

Despite the increase in the number of hypertensive patients, blood pressure did not increase during the 3 year period. Regarding dislipidemia, there was an increase in the number of treated patients along with a decrease in TC and non-HDL over time, although recommend targets were not met.

Nothing to Disclose: TLN, BDP, HVL, AV, ACM, IM, MCC, LR, JP

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm